Speciality Medicines IPO Sees Muted Demand During Bidding

The Speciality Medicines IPO has officially opened for subscription, and it’s now available for investors looking to explore opportunities in the pharmaceutical sector. This IPO is part of the SME segment and is already getting attention in the market.

The issue opened on 20 March 2026 and will remain open until 24 March 2026, giving investors a few days to apply.

Speciality Medicines IPO Subscription Status – Day 3

One of the key highlights of this IPO is that it is a completely fresh issue, which means the company is raising funds to support its business growth and expansion plans.

Talking about the price band, it has been set between ₹117 to ₹124 per share, making it relatively accessible for investors interested in SME IPOs.

Now let’s discuss the most talked-about factor—Grey Market Premium (GMP). As per the latest updates, the GMP for this IPO is currently ₹0, which indicates a neutral market sentiment.
In simple terms, this means there is no strong expectation of listing gains at the moment, and investors are taking a cautious approach.

The company operates in the pharmaceutical space, focusing on speciality medicines, which is a growing segment in India. With increasing demand for advanced healthcare solutions, this sector has long-term potential.

However, a flat GMP usually suggests that investors are waiting to see how the subscription numbers turn out before forming a strong opinion. Market sentiment may change during the IPO period depending on demand.

In conclusion, the Speciality Medicines IPO has opened with steady but cautious interest. While GMP is currently neutral, it’s always important to look beyond just grey market trends. Consider the company’s business model, growth potential, and overall market conditions before making your investment decision.

👉 IPO investing is not just about quick gains—it’s about making informed and balanced choices.